Diagnostic flow chart for targeted detection of Alpha1-antitrypsin deficiency

Prima Divisione di Medicina, Spedali Civili, P.le Spedali Civili no. 1, 25123 Brescia, Italy.
Respiratory Medicine (Impact Factor: 2.92). 04/2006; 100(3):463-70. DOI: 10.1016/j.rmed.2005.06.009
Source: PubMed

ABSTRACT Alpha1-antitrypsin (AAT) deficiency is under-recognized, probably because many individuals affected show no clinical impairment. The targeted detection is a tool to increase its recognition.
We prospectively submitted to AAT serum levels determination, phenotyping and, if doubtful, genotyping: (i) patients with the early onset of emphysema, emphysema in absence of recognized risk or pneumothorax (path P), antineutrophil cytoplasm antibodies (ANCA) positive vasculitis (path V), cervical artery dissection (path A), Periodic acid-Schiff (PAS) positive bodies in the liver cell or unexplained abnormal transaminase level (Path L) [index cases: IC] and (ii) subjects with low-serum alpha1-globulin (path e) and close relatives of patients with AAT deficiency (path r) [non index cases: NIC]. We determined and compared gender, age, AAT serum levels values, the ratio between AAT deficiency subjects identified and all subjects examined (identified/examined). Receiver operating characteristic (ROC) curve was plotted to find the best threshold for AAT serum levels.
Two hundred and eighty-five individuals were examined and 211 with AAT deficiency identified: 66 were IC and 145 NIC. The ratio identified/examined resulted 0.74. A serum level of 120 mg/dL was able to identify AAT deficiency with a specificity of 73% and a sensitivity of 97%. IC showed male prevalence (P=0.005), more advanced age (P=0.02), lower AAT serum levels (P=0.008).
Our protocol is effective to detect AAT deficiency in a selected population. About 120 mg/dL (nephelometric method) is a reliable AAT serum level cut-off for selecting subjects/patients to submit to phenotype or genotype; as compared to NIC, IC are older, mostly male and with lower AAT serum levels.

Download full-text


Available from: Laura Pini, Jul 07, 2015
  • Source
    Lung Diseases - Selected State of the Art Reviews, 03/2012; , ISBN: 978-953-51-0180-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alpha-1 antitrypsin deficiency (AAT) is a hereditary recessive autosomal disease caused by mutations in the AAT gene. This disease is characterized by abnormally low AAT concentrations in plasma, which, in its homozygote form, carries a high risk for the development of early pulmonary emphysema and liver damage. Since the end of the 1980s augmentation therapy with AAT from human plasma has been available for specific treatment of emphysema due to AAT deficiency. Intravenous augmentation therapy has been demonstrated to be safe and weekly infusions of AAT have resulted in plasma AAT concentrations above those considered protective for the lungs. However, life-long weekly infusions are not well accepted by patients, therefore pharmacokinetic studies have been performed to try to individualize the therapeutic regimen in order to obtain adequate trough serum AAT levels with prolonged intervals of administration. Therapeutic regimens administered every two weeks appear to be safe and result in adequate trough serum concentrations, but less-frequent administrations result in trough levels below the target. Alpha-1-antitrypsin deficiency is largely unrecognized and underdiagnosed. The foundation of national and international registries is a valid strategy to increase awareness about the disease and collect information about the natural history of this deficiency. Furthermore, the identification of a large number of patients will allow the development of new clinical trials aimed at finding better treatments for this infrequent condition.
    Therapeutic Advances in Respiratory Disease 03/2008; 2(1):13-21. DOI:10.1177/1753465807088159
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 4 normal alleles of M1, M2, M3, and M4 are the most common gene products of the human alpha-1-antitrypsin (hAAT). Two single substitutions in M1 are responsible for M3 and M4, whereas 2 substitutions in M1 produce M2. Polymerase chain reaction-restriction fragment length polymorphism analysis of the Arg(101)/His(101) sequence variation can separate M1 and M3 from M2 and M4 alleles. To complete the genotyping procedure of hAAT M variants, the exon-V Glu(376)/Asp(376) sequence variation was directly analyzed using a designer primer with a single-base substitution in its sequence. This substitution induced an artificial site for the same restriction enzyme in the polymerase chain reaction product. The new restriction site was present in M1 and M4 but absent in M2 and M3, which can be applied as a rapid reliable means for the M-variant genotyping of hAAT.
    Diagnostic Molecular Pathology 04/2007; 16(1):54-6. DOI:10.1097/01.pdm.0000213465.06387.7f · 2.28 Impact Factor